CD4 and prostate carcinoma: Elevated proportions of Th17 cells have been identified in the total CD4+ T cell populations in several different human solid tumors and hematological malignancies including ovarian, prostate carcinomas, multiple myeloma, and acute myeloid leukemia [7, 20, 28, 29].